Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies

The unprecedented in recent history global COVID-19 pandemic urged the implementation of all existing vaccine platforms to ensure the availability of the vaccines against COVID-19 to every country in the world. Despite the multitude of high-quality papers describing clinical trials of different vacc...

Full description

Saved in:
Bibliographic Details
Main Authors: Liubov I. Kozlovskaya, Anastasia N. Piniaeva, Georgy M. Ignatyev, Ilya V. Gordeychuk, Viktor P. Volok, Yulia V. Rogova, Anna A. Shishova, Anastasia A. Kovpak, Yury Yu. Ivin, Liliya P. Antonova, Kirill M. Mefyod, Lyubov S. Prokosheva, Anna S. Sibirkina, Yuliya Yu. Tarasova, Ekaterina O. Bayurova, Olga S. Gancharova, Victoria V. Illarionova, Grigory S. Glukhov, Olga S. Sokolova, Konstantin V. Shaitan, Anastasia M. Moysenovich, Stanislav A. Gulyaev, Tatiana V. Gulyaeva, Andrey V. Moroz, Larissa V. Gmyl, Elena G. Ipatova, Mikhail P. Kirpichnikov, Alexey M. Egorov, Aleksandra A. Siniugina, Aydar A. Ishmukhametov
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Emerging Microbes and Infections
Subjects:
Vaccine
SARS-CoV-2
COVID-19
neutralizing antibodies
safety
immunogenicity
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2021.1971569
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2021.1971569

Similar Items